Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy
Open accessThe DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
Abstract
Deficiency in DNA damage response (DDR) genes leads to impaired DNA repair functions that will induce genomic instability and facilitate cancer development. However, alterations of DDR genes can serve as biomarkers for the selection of suitable patients to receive specific therapeutics, such as immune checkpoint blockade (ICB) therapy. In addition, certain altered DDR genes can be ideal therapeutic targets through adapting the mechanism of synthetic lethality. Recent studies indicate that targeting DDR can improve cancer immunotherapy by modulating the immune response mediated by cGAS-STING-interferon signaling. Investigations of the interplay of DDR-targeting and ICB therapies provide more effective treatment options for cancer patients. This review introduces the mechanisms of DDR and discusses their crucial roles in cancer therapy based on the concepts of synthetic lethality and ICB. The contemporary clinical trials of DDR-targeting and ICB therapies in breast, colorectal, and pancreatic cancers are included.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 (A) DNA repair systems. Different DNA damages are recognized and repaired through different DNA repair pathways. DNA damages shown here includes ultraviolent light (UV)-induced cyclobutane pyrimidine dimers (TT), benzo[a]pyrene (BaP)-induced bulky DNA adducts, DNA interstrand crosslink, deamination (-NH3, GC to GU pairing), reactive oxygen species (ROS) induced 8-oxoguanine, mismatch DNA pairing (e.g., AG pairing), double-strand breaks (DSBs) induced by ionized radiation, X-ray or cisplatin. Except for direct repair, nucleotide excision repair (NER), base excision repair (BER), mismatch repair (MMR), homologous recombination (HR) and non-homologous end-joining (NHEJ) are shown here. Each DNA repair mechanism comprises three main procedures: recognition, excision, and polymerization. The red circle indicates the defective mutations found in hereditary nonpolyposis colorectal cancer (HNPCC), colorectal cancer (CRC), breast cancer (BC), ovary cancer (OC) and pancreatic cancer (PC). (B) The DNA damage response (DDR). ATM and ATR are activated by DSBs and single-strand breaks. The activated ATM and ATR phosphorylate downstream cell cycle checkpoint kinases, CHK1 and CHK2, which then phosphorylate p53, CDC25, and WEE1. The phosphorylated p53 increases the expression of p21, a potent CDK inhibitor. Phosphorylation of CDC25 (inactive) and WEE1 (active) results in inhibition of CDK activity and leads to cell cycle arrest at G1/S and G2/M transition. Graph created with Biorender.com.](https://figures.cochat.ai/paper-figures/89829d6563874fbf876453a198f74e82/targeting-dna-damage-response-and-immune-checkpoint-for-anticancer-therapy-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Defective DDR can also cause changes in the TME by releasing inflammatory cytokines, which create an immunosuppressive state that helps CRC cells evade immune surveillance, thereby reducing the effectiveness of immunotherapies [51].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [51]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the inherent genomic instability of CRC cells leads to the accumulation of mutations potentially resulting in drug-resistant clones that can expand under treatment [51].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“PARP inhibitors such as olaparib can be effective in cancers with defects in homologous recombination repair and are currently approved for several cancers harboring BRCA mutations, including breast, ovarian, pancreatic, and prostate cancers [51].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [51]
The cited source says what the claim attributes to it.
In the citing paper
“Currently, there are several DDR inhibitors targeting ATM, ATR, DNA-PK, CHK1, or WEE1 being investigated for treating various cancers, including CRC [51].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“Cancer is the major leading cause of death worldwide, accounting for nearly ten million deaths in 2020 [1].”
BackgroundHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Considering the differences between cancerous and normal cells, Hanahan and Weinberg define important hallmarks of cancer, which include autonomous growth signal, evasion of growth inhibitory signal, evasion of apoptosis, unlimited replicative potential, angiogenesis, invasion and metastasis, reprograming energy metab…”
BackgroundHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 1×
“Thus, BRCA1- or BRCA2mutated cancer cells exhibit an increased sensitivity to PARP inhibitors when compared to normal cells [38,56,57] (Figure 3A).”
BackgroundMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 2×
“Functional analysis in a responding patient demonstrated rapid in vivo expansion of neoantigen-specific T cell clones that were reactive to cancer’s mutant neoantigen [129].”
BackgroundPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · cited 1×
“Thus, BRCA1- or BRCA2mutated cancer cells exhibit an increased sensitivity to PARP inhibitors when compared to normal cells [38,56,57] (Figure 3A).”
BackgroundCyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996 · cited 1×
“The binding of cGAMP to STING activates downstream signaling molecules include TANK-binding kinase 1 (TBK1)/interferon regulatory factor 3 (IRF3) and IKKα/β/NFκB to produce type I IFN (IFN-I), IFN-stimulated genes (ISGs), and pro-inflammatory cytokines, such as TNF-α [77,78].”
Background
Cited by
Besse, B., Tostivint, E. P., Park, K., Hartl, S., Forde, P. M., Hochmair, M. J., Awad, M. M., Thomas, M., Goss, G. D., Wheatley‐Price, P., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02808-y · Cited by 200
“Mismatch repair deficiency is associated with greater benefit from immunotherapies 31–34 ; HUDSON therefore evaluated inhibitors of DNA damage response (DDR) and repair pathways in combination with the anti-PD-L1 monoclonal antibody durvalumab.”
The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
Shi, C., Qin, K., Lin, A., Jiang, A., Cheng, Q., Liu, Z., Zhang, J., & Luo, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02469-0 · Cited by 85
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Defective DDR can also cause changes in the TME by releasing inflammatory cytokines, which create an immunosuppressive state that helps CRC cells evade immune surveillance, thereby reducing the effectiveness of immunotherapies [51].”
InfluentialNew Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives
Previtali, V., Bagnolini, G., Ciamarone, A., Ferrandi, G., Rinaldi, F., Myers, S. H., Roberti, M., & Cavalli, A. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00113 · Cited by 87
PD-1/PD-L1 and DNA Damage Response in Cancer
Kciuk, M., Kołat, D., Kałuzińska‐Kołat, Ż., Gawrysiak, M., Drozda, R., Çelik, İ., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040530 · Cited by 50
“The detection of cytosolic DNA by PRRs initiates IFNγ signaling and accompanying innate and adaptive immune responses, similarly as in the case of DAMPs, facilitating the anti-tumor immune response [228].”
BackgroundTargeting the Molecular and Immunologic Features of Leiomyosarcoma
Cope, B. M., Traweek, R. S., Lazcano, R., Keung, E. Z.-Y., Lazar, A. J., Roland, C. L., & Nassif, E. F. (2023) · Cancers · doi:10.3390/cancers15072099 · Cited by 37
“This has been hypothesized to be a result of cytosolic DNA formation caused by double-strand DNA breaks generated by PARP inhibition, which results in increased secretion of proinflammatory cytokines IL-2, TNFα, and IFNγ, leading to subsequent CD8+ T-cell activation [121,122].”
BackgroundLu, H., Zhou, L., Zhang, B., Xie, Y., Yang, H., & Wang, Z. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.939776 · Cited by 32
Genetic, Epidemiological, Clinical, and Therapeutic Trajectories in Colon and Rectal Cancers
Capuozzo, M., Picone, C., Sabbatino, F., Santorsola, M., Caraglia, F., Iervolino, D., Sirica, R., Gualillo, O., Mauro, G. D., Castiello, R., et al. (2025) · Cancers · doi:10.3390/cancers17213438 · Cited by 28
“Other approaches aim to exploit synthetic-lethal vulnerabilities in APC-deficient cells, including modulators of DNA repair, metabolic dependencies, or cell-cycle checkpoints [23].”
Pan, T., Wang, S., & Wang, Z. (2023) · Journal of Cancer · doi:10.7150/jca.84454 · Cited by 26
“Deficiency in DNA damage response (DDR) genes leads to impaired DNA repair functions that will induce genomic instability and facilitate cancer development[47].”
BackgroundCurrent and emerging immunotherapeutic approaches for biliary tract cancers
Yuan, Z., Zeng, T., & Tao, C. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.08.015 · Cited by 21
Huang, C.-H., Huang, Y.-C., Xu, J.-K., Chen, S., Tseng, L.-C., Huang, J.-L., & Lin, C. (2023) · Cells · doi:10.3390/cells12091288 · Cited by 24
“Type I interferons and many ISGs can attract and activate innate and adaptive immune cells, including dendritic cells (DCs), natural killer (NK) cells, CD4+ T-helper cells, and cytotoxic CD8+ T cells [17,20].”
BackgroundSelf-citationTargeting the stimulator of interferon genes (STING) in breast cancer
Ying-rui, M., Bu-Fan, B., Deng, L., Rong, S., & Zhou, Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1199152 · Cited by 18
“For instance, IFI16 has demonstrated anti-tumour effects in triple-negative breast cancer by inducing STING-mediated IFN-I production (Ka et al., 2021; Huang et al., 2022).”
BackgroundAn update on small molecule compounds targeting synthetic lethality for cancer therapy
Luo, J., Li, Y., Zhang, Y., Wu, D., Ren, Y., Liu, J., Wang, C., & Zhang, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116804 · Cited by 19
DNA Damage Response (DDR) and DNA Repair
Vernı̀, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137204 · Cited by 17
“, 2022 [11] shows that the DNA damage response (DDR) is a valuable target for the development of anti-cancer therapies.”
BackgroundGu, W., Zhuang, W., Zhuang, M., He, M., & Li, Z. (2023) · Diagnostic Pathology · doi:10.1186/s13000-023-01401-0 · Cited by 19
“Deficiency in DDR genes were reported to be associated with cancer development and responses to varies therapies [13].”
BackgroundParps in immune response: Potential targets for cancer immunotherapy
Wang, S., Huang, J., Zeng, T., Chen, Y., Xu, Y., & Zhang, B. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116803 · Cited by 21
Self-citationCheng, B., Ding, Z., Hong, Y., Wang, Y., Zhou, Y., Chen, J., Peng, X., & Zeng, C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117347 · Cited by 17
Targeting Cancer Stem Cells through Epigenetic Modulation of Interferon Response
Huang, J.-L., Chen, S., & Lin, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12040556 · Cited by 14
“Consequently, the interferon response is triggered and the efficacy of ICB therapy is enhanced [29,37,133,169,170].”
BackgroundSelf-citationThe emerging role of PARP inhibitors in prostate cancer: A narrative review
Lobianco, L., Calvanese, G., D'Ausilio, D., Rossetti, S., Cecere, S. C., Ventriglia, J., Pisano, C., Tambaro, R., Napoli, M. D., Passarelli, A. M., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103000 · Cited by 16
Hayes, M. N., Cohen‐Gogo, S., Kee, L., Xiong, X., Weiss, A., Layeghifard, M., Ladumor, Y., Valencia-Sama, I., Rajaselvam, A., Kaplan, D. R., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115537 · Cited by 10
How Does cGAS Avoid Sensing Self-DNA under Normal Physiological Conditions?
Zheng, W., Chen, N., Meurens, F., Zheng, W., & Zhu, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914738 · Cited by 13
“The ectopic cytosolic dsDNA may exert both anti-tumorigenic and pro-tumorigenic effects dependent on the specific context as well as the stage of tumor progression [67,68].”
BackgroundPARP inhibition and immunotherapy: a promising duo in fighting cancer
Phillipps, J., Zhou, A. Y., Butt, O. H., & Ansstas, G. (2023) · Translational Cancer Research · doi:10.21037/tcr-23-726 · Cited by 7
Huang, F., Zhang, C., Yang, W., Zhou, Y., Yang, Y., Yang, X., Guo, W., & Wang, B. (2024) · BMC Genomics · doi:10.1186/s12864-024-10055-1 · Cited by 7
“Moreover, the loss of DDR function may determine the response of anticancer treatment, as previously reported [5, 6].”
ResultBRCA and Beyond: Impact on Therapeutic Choices Across Cancer
Tan, J. S. H., Zhang, Z., Goh, H. X., & Ngeow, J. Y. Y. (2024) · Cancers · doi:10.3390/cancers17010008 · Cited by 8
“Pre-clinical studies have also shown that PARP inhibition causes DNA damage that results in increased neoantigen formation, higher tumour mutational burden and elevated immunogenicity [118].”
Graf, T., Boos, L. A., Mehra, T., Miglino, N., Sobottka, B., Rüschoff, J. H., Ibáñez, L. F., Zoche, M., Frauchiger-Heuer, H., Witzel, I., et al. (2025) · Cancers · doi:10.3390/cancers17152435 · Cited by 5
“Additionally, preclinical data have demonstrated that PARP inhibitors may increase TMB, potentially predicting therapeutic response to ICIs [53].”
Evolving Landscape of Precision Medicine in Bladder Cancer: From Challenges to Clinical Impact
Ye, T., Qadir, J., Peng, G., Liu, L., & Cheng, L. (2025) · iLABMED · doi:10.1002/ila2.70045 · Cited by 4
“Alterations in DDR‐related genes, including ERCC2 and ATM , enhance tumor immunogenicity and predict greater ICI sensitivity [124].”
Synthetic RIG-I-Agonist RNA Induces Death of Hepatocellular Carcinoma Cells
Ulloa, B. S., Barber-Axthelm, I. M., Berube, B. J., Duthie, M. S., Reed, S., Savan, R., & Gale, M. (2025) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2024.0195 · Cited by 3
“To determine if RAR signaling of cell death links with signaling of caspase activation, we conducted immunoblot assay to evaluate the abundance of caspase-3 and substrate poly (ADP-ribose) polymerase (PARP), which are major markers of caspase-mediated cell death signaling (Huang et al., 2022).”
Thawani, R., & Kummar, S. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.4591 · Cited by 3
Egea‐Rodriguez, S., Váraljai, R., Nordmann, T. M., Lubis, R., Philip, M., Rambow, F., Roesch, A., Flaig, M. J., Horn, S., Stoll, R., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70094 · Cited by 3
Liguori, L., Ventin, M., Cattaneo, G., Zhang, L., Osipov, A., Sabbatino, F., & Ferrone, C. R. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-025-19056-0 · Cited by 2
Schneider, D., Brown, E. D. L., Gluski, J. M., Mishra, A., Shah, H. A., Sciubba, D. M., & Lo, S.-F. L. (2025) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001161 · Cited by 3
Liu, H., Li, Z., Wang, Y., Li, C., Yan, K., & Ma, Y. (2025) · DNA repair · doi:10.1016/j.dnarep.2025.103857 · Cited by 3
The role of APOBEC mutagenesis in the progression and therapeutic guidance of pancreatic cancer
Yu, X., Shen, G., Liu, Z., Kaysar, P., Shang, X., Ni, B., Zhang, W., Zhou, Y., Xie, Y., & Liu, W. (2025) · Genomics · doi:10.1016/j.ygeno.2025.111098 · Cited by 2
LIG1 overexpression enhances DNA repair and immune escape leading to poor prognosis in osteosarcoma
Fu, W., Tang, G., Tang, Y., Yan, P., & Wang, Q. (2025) · European journal of medical research · doi:10.1186/s40001-025-03647-4 · Cited by 1
“Existing studies indicate that dysregulated expression of DNA repair genes may impair immune surveillance by interfering with antigen presentation, dampening interferon signaling, and upregulating immune checkpoint molecules [28, 29].”
Xinmo, F., Minghua, B., Xu, Q., Weiwei, L., Lin, W., Qinghui, D., Wang, R., & Ji, Z. (2026) · Human Mutation · doi:10.1155/humu/3905052 · Cited by 1
“At the cellular level, DNA damage repair capacity, cell cycle checkpoint control, and antia-poptotic signaling contribute to radioresistance [20, 21].”
Huang, F., Zhang, C., Yang, W., Zhou, Y., Yang, Y., Yang, X., Guo, W., & Wang, B. (2024) · Figshare · doi:10.6084/m9.figshare.26678489
Huang, F., Zhang, C., Yang, W., Zhou, Y., Yang, Y., Yang, X., Guo, W., & Wang, B. (2024) · Figshare · doi:10.6084/m9.figshare.26678486
Zhang, H., Xu, G., & Gou, S. (2026) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2026.113398
Guerrero, P., Sotoca, P., García, A. G., Calvo, J. C., González-Merino, C., de Quevedo, C. G., Subiela, J. D., Bueno, C., Albarran, V., Molina, Á., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag284
“30,31 32–34 Key genes involved in each DNA damage response (DDR) pathway are summarized in Table 1.”
Chromosomal instability in cancer: sources, consequences and new therapeutic opportunities
Serpico, A. F., & Grieco, D. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02940-w
“437 Wee1 inhibition may lead to Cdk2 hyperactivation, impairing proper DNA replication and inducing the accumulation of DSBs. 438 Likewise, Wee1 inhibition may induce Cdk1 overactivation, which forces cells to enter mitosis, bypassing the G2/M checkpoint and ultimately culminating in mitotic catastrophe and cell death.”
InfluentialDeka, R., & Singh, T. R. (2026) · Cancers · doi:10.3390/cancers18203403
BindingDB (2026) · UC San Diego · doi:10.7270/q25m6bn9
Metadata
- Authors
- Huang, J.-L., Chang, Y.-T., Hong, Z.-Y., & Lin, C.-S.
- Affiliations
- Chang Jung Christian University (TW)
- National Sun Yat-sen University (TW)
- Corresponding author
- Lin, Chang-Shen
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-03-17
- Volume
- 23
- Issue
- 6
- Pages
- 3238
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8952261
- OpenAlex
- W4221000214
- Cited by
- 42
- References
- 154
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 6 · 2023: 8 · 2022: 6
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Ministry of Science and Technology, Taiwan (108-2635-B-309-001 and 110-2320-B-037-023. The APC was funded by 110-2320-B-037-023”)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- DNA damage response, immune checkpoint blockade, synthetic lethality, cancer immunotherapy, cGAS-STING pathway, interferon signaling, genomic instability, breast cancer, colorectal cancer, pancreatic cancer
- MeSH terms
- DNA Damage, DNA Repair, Humans, Immunity, Immunotherapy, Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.